104.46USD+2.29%Mkt Cap: 8.27B USDP/E: —Last update: 2026-05-26
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to ad…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap8.27B USD
Enterprise Value6.71B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-425.38M USD
Revenue/Share—
Last Price104.46 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees234
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-25.36
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B6.80
EPS (TTM)-6.06
EPS (Forward)-3.99
52W Range
70.2580% of range113.01
52W High113.01 USD
52W Low70.25 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-34.08%
ROA-30.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-275.21M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-2.18%
Net Debt-1.29B USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio16.14
Quick Ratio15.88
Book Value/Sh14.89 USD
Cash/Share16.30 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)142.05 USD
Target Range116.00 USD – 165.00 USD
# Analysts18
Ownership
Shares Out.73.56M
Float49.00M
Insiders2.76%
Institutions113.29%
Short Interest
Short Ratio8.0d
Short % Float10.77%
Short % Out.6.41%
Shares Short5.06M
Short (prev mo.)4.98M
Technical
SMA 50102.06 (+2.3%)
SMA 20096.50 (+8.3%)
Beta1.15
S&P 52W Chg28.31%
Avg Vol (30d)542.76K
Avg Vol (10d)486.88K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—